{
  "id": 18502671,
  "title": "Coloplast down 4% as UBS sees limited upside after guidance cut",
  "url": "https://urgent.news/2026/11/06/coloplast-down-4-as-ubs-sees-limited-upside-after-guidance-cut",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-06T13:14:00.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/coloplast-down-4-as-ubs-sees-limited-upside-after-guidance-cut-5008024"
  },
  "original_language": "en",
  "account": null,
  "summary": "Coloplast's shares fell over 4% following UBS's downgrade of the company from a \"buy\" to a \"neutral\" rating. The broker cited limited upside potential due to Coloplast's current valuation, which the firm considers justified but has little room for further growth. UBS adjusted its medium-term growth and margin targets, stating that Coloplast trades at a 20% premium to the broader medical technology sector, consistent with slightly lower expected growth.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}